http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004009097-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f4c5ea52d415404c772024a31a6db4b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c1e4a31126817fe85887a127069dc5e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6ec16d37f046e8f22def1c9c7b050879
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de4c2a97b6c6971d567b1e4cec0e732b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_395b4e52248569c69e5e1397eaf84850
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_979f2627f8300f41f240ba24c72c6419
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7084
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7084
filingDate 2003-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96bb38e27b834db66834bc93e82c2b45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3e41bffff909af2350157a61d567782
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b546fd511aaffcf1fce59aba95d13827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7163103de6a620b2f41f31b0afb054ab
publicationDate 2004-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2004009097-A2
titleOfInvention Use of a nad analogue, mono-adp-ribosyl transferase substrate and nad antagonist, for preparing a medicine for treating pathologies related to purinergic receptors
abstract The invention concerns the use of at least one NAD analogue, mono-ADP-ribosyl transferase substrate and NAD antagonist, for preparing a medicine designed to modulate the activity of at least one purinergic receptor, advantageously of type P2X or P2Y, said medicine being particularly designed to treat pathologies wherein purinergic receptors are involved in the physiopathological process or pathologies related to deregulation of the activity of purinergic receptors.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3323415-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106102773-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106163561-A
priorityDate 2002-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0331620-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02055083-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0248395-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02059084-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0393624-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5736529-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5608047-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5019561-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226438198
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135714635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393686
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6323481
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406011
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21226063
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127820761
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226790295
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411706
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID136442480
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID161195
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6022
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129888650
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60961
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID232361586
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226412544
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395240
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID936
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4939

Total number of triples: 49.